|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
41,310,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$ - $ |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Talaris Therapeutics is a late-clinical stage, cell therapy company developing a method of allogeneic hematopoietic stem cell transplantation, called Facilitated Allo-HSCT Therapy, that has the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases and certain severe blood, immune and metabolic disorders. Co.'s lead product candidate, FCR001, which is central to its Facilitated Allo-HSCT Therapy, is an allogeneic cell therapy comprised of stem and immune cells that are procured from a healthy donor, who is also the organ donor in the case of organ transplantation.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
7,000 |
7,000 |
156,150 |
156,150 |
Total Buy Value |
$98,416 |
$98,416 |
$3,991,672 |
$3,991,672 |
Total People Bought |
1 |
1 |
5 |
5 |
Total Buy Transactions |
2 |
2 |
12 |
12 |
Total Shares Sold |
0 |
0 |
0 |
537,376 |
Total Sell Value |
$0 |
$0 |
$0 |
$1,242,339 |
Total People Sold |
0 |
0 |
0 |
1 |
Total Sell Transactions |
0 |
0 |
0 |
27 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Ildstad Suzanne |
Director |
|
2023-02-16 |
4 |
S |
$2.06 |
$6,040 |
D/D |
(2,939) |
3,078,507 |
|
- |
|
Requadt Scott |
Chief Executive Officer |
|
2022-12-30 |
4 |
A |
$0.87 |
$3 |
D/D |
4 |
590,193 |
|
- |
|
Fenton Mary Kay |
Chief Financial Officer |
|
2022-09-10 |
4 |
A |
$0.00 |
$0 |
D/D |
80,000 |
81,000 |
|
- |
|
Krieger Nancy |
Chief Medical Officer |
|
2022-09-10 |
4 |
A |
$0.00 |
$0 |
D/D |
80,000 |
330,233 |
|
- |
|
Zdanowski Michael |
Chief Technology Officer |
|
2022-09-10 |
4 |
A |
$0.00 |
$0 |
D/D |
120,000 |
121,470 |
|
- |
|
Requadt Scott |
Chief Executive Officer |
|
2022-09-10 |
4 |
A |
$0.00 |
$0 |
D/D |
80,000 |
590,189 |
|
- |
|
Ildstad Suzanne |
Chief Scientific Officer |
|
2022-08-22 |
4 |
S |
$2.80 |
$1,470,000 |
D/D |
(525,000) |
3,081,446 |
|
- |
|
Requadt Scott |
Chief Executive Officer |
|
2022-07-29 |
4 |
B |
$4.25 |
$167,374 |
D/D |
39,382 |
508,680 |
2.81 |
- |
|
Requadt Scott |
Chief Executive Officer |
|
2022-07-28 |
4 |
B |
$4.25 |
$13,133 |
D/D |
3,090 |
469,298 |
2.81 |
- |
|
Requadt Scott |
Chief Executive Officer |
|
2022-07-26 |
4 |
B |
$4.24 |
$23,439 |
D/D |
5,528 |
466,208 |
2.81 |
- |
|
Nader Francois |
Director |
|
2022-07-25 |
4 |
A |
$0.00 |
$0 |
I/I |
138,500 |
386,932 |
|
- |
|
Nader Francois |
Director |
|
2022-07-25 |
4 |
D |
$0.00 |
$0 |
D/D |
(138,500) |
0 |
|
- |
|
Requadt Scott |
Chief Executive Officer |
|
2022-07-22 |
4 |
B |
$3.75 |
$35,412 |
D/D |
9,444 |
460,680 |
2.81 |
- |
|
Nader Francois |
Director |
|
2022-07-21 |
4/A |
D |
$0.00 |
$0 |
I/I |
(248,432) |
147,255 |
|
- |
|
Nader Francois |
Director |
|
2022-07-21 |
4 |
B |
$3.72 |
$135,780 |
D/D |
36,500 |
138,500 |
2.39 |
- |
|
Nader Francois |
Director |
|
2022-07-21 |
4 |
A |
$0.00 |
$0 |
I/I |
248,432 |
248,432 |
|
- |
|
Nader Francois |
Director |
|
2022-07-21 |
4 |
D |
$0.00 |
$0 |
I/I |
(248,432) |
87,735 |
|
- |
|
Nader Francois |
Director |
|
2022-07-20 |
4 |
B |
$3.62 |
$188,240 |
D/D |
52,000 |
102,000 |
2.39 |
- |
|
Nader Francois |
Director |
|
2022-07-19 |
4 |
B |
$3.52 |
$176,000 |
D/D |
50,000 |
50,000 |
2.39 |
- |
|
Zdanowski Michael |
Chief Technology Officer |
|
2021-12-31 |
4 |
A |
$13.00 |
$19,110 |
D/D |
1,470 |
1,470 |
|
- |
|
Fenton Mary Kay |
Chief Financial Officer |
|
2021-12-31 |
4 |
A |
$13.00 |
$13,000 |
D/D |
1,000 |
1,000 |
|
- |
|
Requadt Scott |
Chief Executive Officer |
|
2021-12-31 |
4 |
A |
$13.00 |
$19,110 |
D/D |
1,470 |
451,236 |
|
- |
|
Nader Francois |
Director |
|
2021-12-15 |
4 |
GD |
$0.00 |
$0 |
I/I |
59,520 |
336,167 |
|
- |
|
Ildstad Suzanne |
Chief Scientific Officer |
|
2021-11-17 |
4 |
GA |
$0.00 |
$0 |
I/I |
1,200,000 |
1,200,000 |
|
- |
|
Ildstad Suzanne |
Chief Scientific Officer |
|
2021-11-17 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,200,000 |
3,606,446 |
|
- |
|
89 Records found
|
|
Page 3 of 4 |
|
|